MedTrace Logo

Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy

NCT00876538 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2016-11-22

No results posted yet for this study

Summary

The purpose of this study is to test the effect of TRO19622 on peripheral neuropathy scores after 6 weeks treatment and is based on the separate assessment of pain and dysesthesia scores.

Conditions

  • Chemotherapy-Induced Peripheral Neuropathy

Interventions

DRUG

Olesoxime (TRO19622)

2 capsules of TRO19622 (330 mg) once day with the noon meal

DRUG

Placebo Control

Placebo Control 2 capsules once day with the noon meal

Sponsors & Collaborators

Principal Investigators

  • Ivan Krakowski, MD · Centre Alexis Vautrin / Département d'Oncologie Médicale/ Nancy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00876538 on ClinicalTrials.gov